repurposing drugs for cancer treatment
creating new drugs to treat cancer can be a long and arduous process. from development to clinical trials, it can take years and a lot of money and grants for researchers to get new drugs off the ground and into the hands of patients.
by repurposing existing drugs that can have beneficial off-label effects, they significantly reduce the process time, making new therapies more accessible in the short term rather than the long term.
in the case of epalrestat for lung cancer, the drug, which is already approved for use in japan, china, and india, can be fast-tracked into the hands of clinicians and their patients if it becomes approved for this specific use in canada.
future directions
as of writing, epalrestat is not approved in canada. the new study results have paved the way for high-level clinical trials conducted by the food and drug administration (fda) in the united states. however, there is no current news on whether canada will follow suit in the upcoming years.
if the fda grants approval for epalrestat for lung cancer treatment, it can be brought to people with lung cancer sooner, but the trials mentioned above are still ongoing.
using drugs off-label or repurposed is a longstanding tradition that has helped medical researchers, clinicians, and patients find new ways to treat old diseases. if all goes well with epalrestat, those living with lung cancer will have another potentially lifesaving tool to use during their treatment.